Kronos Bio (NASDAQ:KRON) Trading Up 1.5% – Time to Buy?

Kronos Bio, Inc. (NASDAQ:KRON)’s share price was up 1.5% during trading on Monday . The stock traded as high as $0.88 and last traded at $0.88. Approximately 54,089 shares changed hands during mid-day trading, a decline of 85% from the average daily volume of 366,536 shares. The stock had previously closed at $0.87.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised Kronos Bio to a “hold” rating in a report on Saturday, June 21st.

Kronos Bio Trading Up 1.5%

The firm has a fifty day simple moving average of $0.80 and a 200 day simple moving average of $0.88. The stock has a market cap of $53.72 million, a price-to-earnings ratio of -0.82 and a beta of 1.64.

Institutional Investors Weigh In On Kronos Bio

Several large investors have recently modified their holdings of KRON. Velan Capital Investment Management LP bought a new stake in shares of Kronos Bio in the 4th quarter valued at approximately $33,000. GTS Securities LLC bought a new stake in shares of Kronos Bio in the 4th quarter valued at approximately $48,000. Squarepoint Ops LLC bought a new stake in Kronos Bio during the 4th quarter worth approximately $93,000. Deuterium Capital Management LLC bought a new stake in Kronos Bio during the 1st quarter worth approximately $121,000. Finally, Kennedy Capital Management LLC grew its position in Kronos Bio by 8.7% during the 4th quarter. Kennedy Capital Management LLC now owns 149,251 shares of the company’s stock worth $142,000 after acquiring an additional 12,007 shares during the last quarter. 64.09% of the stock is currently owned by institutional investors.

About Kronos Bio

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.